You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 4
  • EPV279/#351 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline brca mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer

Citation Tools

Article menu

Download PDFPDF

E-Posters
E-Poster Viewing
EPV279/#351 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline brca mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Konstantinopoulos P, González-Martín A, Cruz F, et al
EPV279/#351 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline brca mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer
International Journal of Gynecologic Cancer 2021;31:A139-A140.